Abstract
Typically, unchecked pancreatic cell proliferation results in the development of pancreatic cancer, which has the potential to spread to other bodily organs. About 90% of instances of pancreatic cancer are pancreatic adenocarcinomas. About 10-20% of pancreatic carcinomas are resectable and potentially curable, and the 5-year survival rate is only 4%; as a result, the majority of pancreatic cancer treatments are palliative in nature. Surgical resection is the only curative treatment; however, because of late diagnosis, the majority of patients appear at an advanced stage, and only a small percentage (10-20%) of them are candidates for surgery. Due to pancreatic cancer's strong resistance to practically all chemotherapeutic drugs and conventional radiotherapies, conventional radiation and chemotherapies have little effectiveness in extending patients' overall life. A lot of scientific studies, however, frequently use the metaphorical term 'double-edged sword' to indicate how autophagy plays a different function in cancer. The use of autophagy inhibitors is thought to be advantageous in combining antineoplastic drugs to improve the sensitivity of cancer cells to therapeutic compounds that activate autophagy. In this review, we aim to look into autophagy along with searching for the most effective strategy in order to treat pancreatic adenocarcinoma with the least drug resistance.